The comparative risk of new-onset diabetes after prescription of drugs for cardiovascular risk prevention in primary care: A national cohort study

BMJ Open

Volumn 3, Issue 11, 2013, Pages

  Currie, Olivia ^a   Mangin, Dee ^a,b   Williman, Jonathan ^a   McKinnon Gee, Bianca ^c   Bridgford, Paul ^c  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b MCMASTER UNIVERSITY   (Canada)

^c Pegasus Health Charitable Ltd   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DICLOFENAC; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; THIAZIDE DIURETIC AGENT;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE COURSE; ELECTRONIC PRESCRIBING; FEMALE; FOLLOW UP; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NEW ZEALAND; PRIMARY MEDICAL CARE;

EID: 84889594485     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2013-003475     Document Type: Article

References (29)

1. Taylor F, Huffman MD, Macedo AF, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2013;(1):CD004816.
2. Culver AL, Ockene IS, Balasubramanian R, et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch Intern Med 2012;172:144-52.
3. Alberton M, Wu P, Druyts E, et al. Adverse events associated with individual statin treatments for cardiovascular disease: an indirect comparison meta-analysis. QJM 2012;105:145-57.
4. Mills EJ, Wu P, Chong G, et al. Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials. QJM 2011;104:109-24.
5. Preiss D, Sattar N. Statins and the risk of new-onset diabetes: a review of recent evidence. Curr Opin Lipidol 2011;22:460-6.
6. Preiss D, Seshasai S, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 2011;305:2556-64.
7. Sattar N, Preiss D, Murray H, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010;375:735-42.
8. Ridker P, Danielson E, Fonseca F, et al. Rosuvastatin to prevent vascular events in men and women with elevated CRP. N Engl J Med 2008;359:2195-207.
9. Koh KK, Quon MJ, Han SH, et al. Differential metabolic effects of pravastatin and simvastatin in hypercholesterolemic patients. Atherosclerosis 2009;204:483-90.
10. Koh KK, Quon MJ, Han SH, et al. Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients. J Am Coll Cardiol 2010;55:1209-16.
11. Cholesterol Treatment Trialists' Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78.
12. Movahed MR, Sattur S, Hashemzadeh M. Independent association between type 2 diabetes mellitus and hypertension over a period of 10 years in a large inpatient population. Clin Exp Hypertens 2010;32:198-201.
13. Verdecchia P, Reboldi G, Angeli F, et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004;43:963-9.
14. Dagenais GR Auger P, Bogaty P, et al. Increased occurrence of diabetes in people with ischemic cardiovascular disease and general and abdominal obesity. Can J Cardiol 2003;19:1387-91.
15. Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales: population based cohort study using QResearch database. BMJ 2010;49:340.
16. Source: Ministry of Health, Pharmaceutical Collection.
17. Smith SM, Gong Y, Turner ST, et al. Blood pressure responses and metabolic effects of hydrochlorothiazide and atenolol. Am J Hypertens 2012;25:359-65.
18. Mancia G, Grassi G, Zanchetti A. New-onset diabetes and antihypertensive drugs. J Hypertens 2006;24:3-10.
19. Aksnes T, Reims H, Kjeldsen S, et al. Antihypertensive treatment and new onset diabetes mellitus. Curr Hypertens Rep 2005;7:298-303.
20. New Zealand Guidelines Group. New Zealand primary care handbook 2012. 3rd edn. Wellington: New Zealand Guidelines Group, 2012.
21. Dean AG SK, Soe MM. OpenEpi: Open Source Epidemiologic Statistics for Public Health, Version 2.3.1. http://www.OpenEpi.com, updated 2011/23/06 (accessed 23 Oct 2012).
22. Statistics New Zealand. http://www.stats.govt.nz/infoshare
23. Wang K-L, Liu C-J, Chao T-F, et al. Statins, risk of diabetes, and implications on outcomes in the general population. J Am Coll Cardiol 2012;60:1231-8.
24. Rautio N, Jokelainen J, Oksa H. Do statins interfere with lifestyle intervention in the prevention of diabetes inprimary healthcare? One-year follow-up of the FIN-D2D project. BMJ Open 2012;2:e001472.
25. Ma T, Tien L, Fang C-L, et al. Statins and new-onset diabetes: a retrospective longitudinal cohort study. Clin Ther 2012;34:1977-83.
26. Carter AA, Gomes T, Camacho X, et al. Risk of incident diabetes among patients treated with statins: population based study. BMJ 2013:346:f4356.
27. Abdullah A, Stoelwinder J, Shortreed S, et al. The duration of obesity and the risk of type 2 diabetes. Public Health Nutr 2011;14:119-26.
28. Golomb BA, Koperski S, White HL. Statins raise glucose preferentially among men who are older and at greater metabolic risk. Circulation 2012;125:A055.
29. Tu K. Diabetics can be identified in an electronic medical record using laboratory tests and prescriptions. J Clin Epidemiol 2011;64:431-5.